Intratumoral heterogeneity may be responsible for chemotherapy resistance in patients with small cell lung cancer
HOUSTON – Small cell lung cancer (SCLC) accounts for 14% of all lung cancers and is often rapidly resistant to chemotherapy, resulting in poor clinical outcomes. Treatment has changed little for decades, but a study at The University of Texas MD Anderson Cancer Center found that chemotherapy results in increased heterogeneity within the tumor, leading…
Details